15.11

3.04% 0.4504

Theravance Biopharma Inc (TBPH)

Overview News Price History Option Chain Financials Discussions Forecast

Theravance Biopharma Inc stock is traded at $15.11, with a volume of 368.56K. It is up +3.04% in the last 24 hours and up +4.82% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Previous Close:

$14.66

Open:

$14.75

24h Volume:

368.56K

Relative Volume:

0.92

Market Cap:

$762.97M

Revenue:

$62.02M

Net Income/Loss:

$-45.65M

P/E Ratio:

-16.42

EPS:

-0.92

Net Cash Flow:

$-9.60M

1W Performance:

+5.63%

1M Performance:

+4.82%

6M Performance:

+45.66%

1Y Performance:

+82.43%

1-Day Range:

$14.46

$15.20

1-Week Range:

$13.95

$15.20

52-Week Range:

$7.90

$15.20

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name

Theravance Biopharma Inc

Sector

Healthcare (1139)

Industry

Biotechnology (635)

Phone

650-808-6000

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TBPH's Discussions on Twitter

Compare TBPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TBPH Theravance Biopharma Inc	15.15	738.30M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	425.69	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	641.80	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	432.61	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	822.11	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	183.82	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-12-25	Initiated	B. Riley Securities	Buy
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-12-24	Initiated	BTIG Research	Buy
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-07-20	Initiated	JP Morgan	Overweight
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight
May-13-20	Initiated	Cowen	Outperform
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral
Oct-29-19	Initiated	H.C. Wainwright	Buy
Mar-29-18	Resumed	Piper Jaffray	Overweight
Aug-17-17	Initiated	Evercore ISI	Outperform
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
May-11-17	Reiterated	Needham	Buy
Dec-21-16	Initiated	Needham	Buy
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform
Jun-20-16	Initiated	Guggenheim	Buy
Jun-20-16	Reiterated	Leerink Partners	Outperform
May-12-16	Initiated	Leerink Partners	Outperform
May-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Feb-03-15	Upgrade	Robert W. Baird	Underperform → Neutral

View All

Theravance Biopharma Inc Stock (TBPH) Latest News

09:19 AM

News impact scoring models applied to Theravance Biopharma Inc.2025 Year in Review & Free Community Consensus Stock Picks - newser.com

09:19 AM

09:02 AM

Can Theravance Biopharma Inc. (0TB) stock sustain revenue momentumMarket Activity Report & Stepwise Entry and Exit Trade Signals - newser.com

09:02 AM

08:14 AM

Is Theravance Biopharma Inc. stock cheap at current valuationWeekly Stock Summary & Community Driven Trade Alerts - newser.com

08:14 AM

04:37 AM

Will a bounce in Theravance Biopharma Inc. offer an exitQuarterly Profit Review & Capital Efficiency Focused Strategies - newser.com

04:37 AM

04:23 AM

Can Theravance Biopharma Inc. stock maintain operating marginsWeekly Trend Report & Community Trade Idea Sharing Platform - newser.com

04:23 AM

02:45 AM

What consensus target says about Theravance Biopharma Inc. (0TB) stockInflation Watch & Verified Short-Term Trading Plans - newser.com

02:45 AM

02:43 AM

Is Theravance Biopharma Inc. (0TB) stock a momentum leaderTreasury Yields & Safe Capital Growth Tips - newser.com

02:43 AM

01:00 AM

Can Theravance Biopharma Inc. stock deliver consistent earnings growth2025 EndofYear Setup & Trade Opportunity Analysis Reports - newser.com

01:00 AM

Nov 02, 2025

Can Theravance Biopharma Inc. (0TB) stock hit consensus price targets2025 Price Targets & Safe Entry Trade Signal Reports - newser.com

Nov 02, 2025

Why Theravance Biopharma Inc. (0TB) stock benefits from AI revolutionMarket Performance Recap & Reliable Breakout Forecasts - newser.com

Nov 02, 2025

Why Theravance Biopharma Inc. stock is in analyst buy zone2025 Support & Resistance & Reliable Breakout Forecasts - newser.com

Nov 02, 2025

Why Theravance Biopharma Inc. (0TB) stock remains stableJuly 2025 Sentiment & Fast Exit Strategy with Risk Control - newser.com

Nov 02, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Nov 02, 2025

Theravance Biopharma Inc. stock trendline breakdownJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com

Nov 02, 2025

Will Theravance Biopharma Inc. stock see insider buyingAnalyst Upgrade & Technical Pattern Based Signals - newser.com

Nov 02, 2025

Nov 01, 2025

Can Theravance Biopharma Inc. stock attract ESG capital inflowsJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com

Nov 01, 2025

Oct 31, 2025

How to escape a deep drawdown in Theravance Biopharma Inc.July 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com

Oct 31, 2025

What to expect from Theravance Biopharma Inc. in the next 30 daysIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com

Oct 31, 2025

Oct 30, 2025